Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.

Increasing evidence supports the use of magnetic resonance imaging (MRI)-ultrasound fusion-targeted prostate biopsy (MRF-TB) to improve the detection of clinically significant prostate cancer (PCa) while limiting detection of indolent disease compared to systematic 12-core biopsy (SB).

To compare MRF-TB and SB results and investigate the relationship between biopsy outcomes and prebiopsy MRI.

Retrospective analysis of a prospectively acquired cohort of men presenting for prostate biopsy over a 26-mo period. A total of 601 of 803 consecutively eligible men were included.

All men were offered prebiopsy MRI and assigned a maximum MRI suspicion score (mSS). Men with an MRI abnormality underwent combined MRF-TB and SB.

Detection rates for all PCa and high-grade PCa (Gleason score [GS] ≥7) were compared using the McNemar test.

MRF-TB detected fewer GS 6 PCas (75 vs 121; p

MRF-TB detects more high-grade PCas than SB while limiting detection of GS 6 PCa in men presenting for prostate biopsy. These findings suggest that prebiopsy multiparametric MRI and MRF-TB should be considered for all men undergoing prostate biopsy. In addition, mSS in conjunction with biopsy indications may ultimately help in identifying men at low risk of high-grade cancer for whom prostate biopsy may not be warranted.

We examined how magnetic resonance imaging (MRI)-targeted prostate biopsy compares to traditional systematic biopsy in detecting prostate cancer among men with suspicion of prostate cancer. We found that MRI-targeted biopsy detected more high-grade cancers than systematic biopsy, and that MRI performed before biopsy can predict the risk of high-grade cancer.

European urology. 2015 Jun 22 [Epub ahead of print]

Xiaosong Meng, Andrew B Rosenkrantz, Neil Mendhiratta, Michael Fenstermaker, Richard Huang, James S Wysock, Marc A Bjurlin, Susan Marshall, Fang-Ming Deng, Ming Zhou, Jonathan Melamed, William C Huang, Herbert Lepor, Samir S Taneja

Department of Urology, NYU Langone Medical Center, New York, NY, USA. , Department of Radiology, NYU Langone Medical Center, New York, NY, USA. , School of Medicine, NYU Langone Medical Center, New York, NY, USA. , School of Medicine, NYU Langone Medical Center, New York, NY, USA. , Department of Urology, NYU Langone Medical Center, New York, NY, USA. , Department of Urology, NYU Langone Medical Center, New York, NY, USA; Department of Urology, New York Hospital Queens, Flushing, NY, USA. , Department of Urology, NYU Langone Medical Center, New York, NY, USA; Department of Urology, St. Barnabas Hospital, Bronx, NY, USA. , Department of Urology, NYU Langone Medical Center, New York, NY, USA. , Department of Pathology, NYU Langone Medical Center, New York, NY, USA. , Department of Pathology, NYU Langone Medical Center, New York, NY, USA. , Department of Pathology, NYU Langone Medical Center, New York, NY, USA. , Department of Urology, NYU Langone Medical Center, New York, NY, USA. , Department of Urology, NYU Langone Medical Center, New York, NY, USA. , Department of Urology, NYU Langone Medical Center, New York, NY, USA; Department of Radiology, NYU Langone Medical Center, New York, NY, USA.  

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe